Clinical Trials Logo

Advanced Malignant Solid Tumors clinical trials

View clinical trials related to Advanced Malignant Solid Tumors.

Filter by:

NCT ID: NCT04908046 Recruiting - Clinical trials for Advanced Malignant Solid Tumors

A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors

Start date: May 27, 2021
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety, tolerability and PK profile of HMPL-295S1 and determine MTD and/or RP2D in patients with advanced malignant solid tumor. It will be extended to enroll 10-15 patients at this dose after RP2D is determined, as to further evaluate the safety of RP2D and the preliminary efficacy of HMPL-295S1. In addition, an exploratory study on the pharmacokinetic biomarkers of HMPL-295S1 is planned in this study.

NCT ID: NCT04328506 Completed - Clinical trials for Advanced Malignant Solid Tumors

Bioequivalency Study of CM082 Tablet in Healthy Volunteers

Start date: June 1, 2020
Phase: Phase 1
Study type: Interventional

The main objective of this study is to evaluate the bioequivalency of two preparations of CM082 tablet in Chinese healthy volunteers.

NCT ID: NCT04226066 Recruiting - Clinical trials for Advanced Malignant Solid Tumors

Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors

Start date: November 20, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This open, dose-escalation and extended PhI/IIa clinical trial aims to evaluate the safety, tolerability of T601 as a single-agent as well as combined with prodrug 5-FC to treat patients with advanced malignant solid tumors and to explore the pharmacokinetic characteristics of T601, 5-FC, 5-FU, FBAL, which includes PhI study of dose-escalation study and Ph IIa study of extending study.

NCT ID: NCT04126668 Completed - Clinical trials for Advanced Malignant Solid Tumors

A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers

Start date: December 19, 2019
Phase: Phase 1
Study type: Interventional

The main objective of this study is to evaluate the Effect of Food on the Pharmacokinetics of CM082 tablet.

NCT ID: NCT03792958 Active, not recruiting - Clinical trials for Advanced Malignant Solid Tumors

Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors

Start date: February 26, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Dosing of CM082 tablets in Chinese Patients With Advanced Malignant Solid Tumors

NCT ID: NCT03047811 Recruiting - Clinical trials for Advanced Malignant Solid Tumors

The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors

Start date: August 26, 2016
Phase: N/A
Study type: Interventional

The study of targeted NY-ESO-1 T cell receptor (TCR) genetic modified autologous T cells treatment of advanced solid tumors 1. The main purpose - security and ORR; 2. A secondary purpose - median progression-free surial;1 year, 2 years, total 5 years survival rate;The quality of life.

NCT ID: NCT02045095 Terminated - Clinical trials for Advanced Malignant Solid Tumors

A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

Start date: January 31, 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety and tolerability (establish maximum tolerated dose [MTD], inform the recommended phase 2 dose [RP2D], and identify the dose-limiting toxicities [DLTs]) of MLN7243.

NCT ID: NCT01128842 Completed - Clinical trials for Advanced Malignant Solid Tumors

A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor

Start date: April 2010
Phase: Phase 1
Study type: Interventional

This is an open-label, phase 1 study of a single cohort of neratinib (HKI-272) in combination with capecitabine.

NCT ID: NCT00997360 Withdrawn - Clinical trials for Advanced Malignant Solid Tumors

Study of PKI-179 Administered Orally to Subjects With Solid Tumors

Start date: February 2010
Phase: Phase 1
Study type: Interventional

This is an open label dose escalation study to find the maximum tolerated dose (MTD) of PKI-179 in subjects with solid tumors. Part 1 of the study will be the dose estimation phase and will be open to subjects with all solid tumors. Part 2 will be the dose confirmation phase and will be open to subjects with breast, non small cell lung, ovarian, endometrial, or colorectal cancer or glioblastoma. All subjects will receive daily oral dosing of PKI-179. A continuous reassessment method (CRM) design will be used, which will take into account dose limiting toxicity (DLT) information from each dose level explored in order to determine the next dose level.

NCT ID: NCT00958724 Completed - Clinical trials for Advanced Malignant Solid Tumors

Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors

Start date: July 2009
Phase: Phase 1
Study type: Interventional

The purposes of this study are to evaluate the safety and tolerability of neratinib in combination with vinorelbine at the maximum tolerated dose (MTD) determined in a previous study, or to determine a lower MTD of the two drugs, as well as to obtain preliminary information on whether the combination of the two drugs has any effect on solid tumors in Japanese patients.